Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 01, 2019
Source ID
10.1016/j.msard.2018.09.038

Entities

People

  • Daniel Ontaneda
  • Jaanai Babb
  • Jacqueline Nicholas
  • Jason P. Mendoza
  • Jia Zhou
  • Katherine Riester
  • Matthew Carraro
  • Mehul Jhaveri
  • Qiang Hou
  • Terrie Livingston

Organizations

  • Biogen
  • National Institutes of Health
  • National Multiple Sclerosis Society
  • Patient-Centered Outcomes Research Institute
  • United States Department of Defense